BR0316375A - Diazinopirimidinas - Google Patents

Diazinopirimidinas

Info

Publication number: BR0316375A
Authority: BR; Brazil
Prior art keywords: same; diazinopyrimidines; relates; present; report
Prior art date: 2002-11-18

Application number

BR0316375-0A

Other languages

English (en)

Portuguese (pt)

Inventor

Jian Jeffrey Chen

Kin-Chun Luk

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-18

Filing date

2003-11-12

Publication date

2005-10-04

2003-11-12 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-10-04 Publication of BR0316375A publication Critical patent/BR0316375A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)

BR0316375-0A 2002-11-18 2003-11-12 Diazinopirimidinas BR0316375A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42765202P	2002-11-18	2002-11-18
PCT/EP2003/012652 WO2004046152A1 (fr)	2002-11-18	2003-11-12	Diazyinopyrimidines

Publications (1)

Publication Number	Publication Date
BR0316375A true BR0316375A (pt)	2005-10-04

Family

ID=32326577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0316375-0A BR0316375A (pt)	2002-11-18	2003-11-12	Diazinopirimidinas

Country Status (14)

Country	Link
US (2)	US6943158B2 (fr)
EP (1)	EP1565475B1 (fr)
JP (1)	JP2006514624A (fr)
KR (1)	KR20050075028A (fr)
CN (1)	CN100357293C (fr)
AT (1)	ATE427951T1 (fr)
AU (1)	AU2003283393A1 (fr)
BR (1)	BR0316375A (fr)
CA (1)	CA2506565A1 (fr)
DE (1)	DE60327097D1 (fr)
MX (1)	MXPA05005028A (fr)
PL (1)	PL377620A1 (fr)
RU (1)	RU2340618C2 (fr)
WO (1)	WO2004046152A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2332527A3 (fr) *	2004-10-20	2011-11-16	Resverlogix Corp.	Flavanoides et Isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
AU2006275514B2 (en)	2005-07-29	2012-04-05	Resverlogix Corp.	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
JPWO2008001929A1 (ja) *	2006-06-28	2009-12-03	あすか製薬株式会社	炎症性腸疾患の処置剤
EP1918284A1 (fr) *	2006-10-30	2008-05-07	Glaxo Group	Pyrimidines d'hydrazine comme inhibiteurs de protease de cysteine
KR101444489B1 (ko) *	2007-02-01	2014-09-24	리스버로직스 코퍼레이션	심혈관 질환을 예방 및 치료하기 위한 화합물
US8114995B2 (en)	2008-06-26	2012-02-14	Resverlogix Corp.	Methods of preparing quinazolinone derivatives
DE102008063561A1 (de) *	2008-12-18	2010-08-19	Bayer Cropscience Ag	Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
ES2542835T3 (es)	2009-01-08	2015-08-12	Resverlogix Corporation	Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
WO2010099139A2 (fr)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Thérapie anti-cancer combinée
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
KR101841003B1 (ko)	2009-03-18	2018-03-22	리스버로직스 코퍼레이션	신규한 소염제
US9757368B2 (en)	2009-04-22	2017-09-12	Resverlogix Corp.	Anti-inflammatory agents
WO2012088266A2 (fr)	2010-12-22	2012-06-28	Incyte Corporation	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
WO2012149014A1 (fr)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
US9610251B2 (en)	2011-11-01	2017-04-04	Resverlogix Corp.	Pharmaceutical compositions for substituted quinazolinones
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
SI2861595T1 (sl)	2012-06-13	2017-04-26	Incyte Holdings Corporation	Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (fr)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Amines cycliques servant d'inhibiteurs de bromodomaines
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
WO2014096965A2 (fr)	2012-12-21	2014-06-26	Rvx Therapeutics Inc.	Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine
ES2657451T3 (es) *	2013-04-19	2018-03-05	Incyte Holdings Corporation	Heterocíclicos bicíclicos como inhibidores del FGFR
CN103757026B (zh) *	2013-12-20	2017-04-05	广州圣露生物技术有限公司	FGFR2b胞外段的基因序列、多肽及其应用
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (fr)	2015-02-20	2024-02-27	Incyte Corporation	Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr
CN107530356A (zh)	2015-03-13	2018-01-02	雷斯韦洛吉克斯公司	用于治疗补体相关疾病之组合物及治疗方法
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
JP7012152B2 (ja)	2017-10-05	2022-02-10	フルクラムセラピューティクス，インコーポレイテッド	Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
KR20210018265A (ko)	2018-05-04	2021-02-17	인사이트 코포레이션	Fgfr 억제제의 고체 형태 및 이의 제조 방법
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CR20220285A (es)	2019-12-04	2022-10-27	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021113479A1 (fr)	2019-12-04	2021-06-10	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021146424A1 (fr)	2020-01-15	2021-07-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (fr)	2021-06-09	2024-04-17	Incyte Corporation	Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1353534A (en)	1971-07-13	1974-05-22	Roche Products Ltd	Pyrimidotriazines and a process for the manufacture thereof
US4025510A (en) *	1975-12-01	1977-05-24	E. I. Du Pont De Nemours And Company	2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines
AU776250B2 (en) *	1999-10-21	2004-09-02	F. Hoffmann-La Roche Ag	Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
BR0113628A (pt) *	2000-08-31	2003-07-01	Hoffmann La Roche	7-oxo-piridopirimidinas como inibidores de uma proliferação celular
US6642381B2 (en) *	2001-12-27	2003-11-04	Hoffman-La Roche Inc.	Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors

2003
- 2003-11-12 AT AT03775346T patent/ATE427951T1/de not_active IP Right Cessation
- 2003-11-12 WO PCT/EP2003/012652 patent/WO2004046152A1/fr not_active Ceased
- 2003-11-12 JP JP2004552580A patent/JP2006514624A/ja active Pending
- 2003-11-12 BR BR0316375-0A patent/BR0316375A/pt not_active IP Right Cessation
- 2003-11-12 CN CNB2003801035760A patent/CN100357293C/zh not_active Expired - Fee Related
- 2003-11-12 DE DE60327097T patent/DE60327097D1/de not_active Expired - Fee Related
- 2003-11-12 RU RU2005119281/04A patent/RU2340618C2/ru not_active IP Right Cessation
- 2003-11-12 CA CA002506565A patent/CA2506565A1/fr not_active Abandoned
- 2003-11-12 PL PL377620A patent/PL377620A1/pl not_active Application Discontinuation
- 2003-11-12 AU AU2003283393A patent/AU2003283393A1/en not_active Abandoned
- 2003-11-12 EP EP03775346A patent/EP1565475B1/fr not_active Expired - Lifetime
- 2003-11-12 MX MXPA05005028A patent/MXPA05005028A/es active IP Right Grant
- 2003-11-12 KR KR1020057008919A patent/KR20050075028A/ko not_active Ceased
- 2003-11-18 US US10/715,666 patent/US6943158B2/en not_active Expired - Fee Related
2005
- 2005-07-27 US US11/190,292 patent/US20050261284A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA05005028A (es)	2005-08-03
US20040097493A1 (en)	2004-05-20
EP1565475A1 (fr)	2005-08-24
PL377620A1 (pl)	2006-02-06
US6943158B2 (en)	2005-09-13
EP1565475B1 (fr)	2009-04-08
JP2006514624A (ja)	2006-05-11
WO2004046152A1 (fr)	2004-06-03
KR20050075028A (ko)	2005-07-19
CN1714093A (zh)	2005-12-28
US20050261284A1 (en)	2005-11-24
CN100357293C (zh)	2007-12-26
AU2003283393A1 (en)	2004-06-15
ATE427951T1 (de)	2009-04-15
RU2005119281A (ru)	2006-03-20
CA2506565A1 (fr)	2004-06-03
RU2340618C2 (ru)	2008-12-10
DE60327097D1 (de)	2009-05-20

Publication	Publication Date	Title
BR0316375A (pt)	2005-10-04	Diazinopirimidinas
MXPA05013752A (es)	2006-03-08	Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
WO2003016282A3 (fr)	2003-04-24	Nouveaux 1h-dihydropyrazoles substitues et leurs procedes de preparation et d'utilisation
BRPI0415449A (pt)	2006-12-19	combinações de compostos ativos fungicidas sinergìsticos
BRPI0412347A (pt)	2006-09-05	2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR0307351A (pt)	2004-12-14	Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BRPI0407967A (pt)	2006-03-07	processo de uma etapa para a preparação de derivados anticonvulsivantes
MXPA03009840A (es)	2004-04-02	Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
BRPI0414111A (pt)	2006-10-31	inibidores heterocìclicos de mek e métodos de uso dos mesmos
BRPI0412851A (pt)	2006-10-03	benzamidazóis de n-metila-substituìdos
WO2004062613A3 (fr)	2004-11-04	Inhibiteurs d'integrase hiv
BRPI0511933B8 (pt)	2021-05-25	derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
ATE484508T1 (de)	2010-10-15	Furylverbindungen
BRPI0408353A (pt)	2006-03-21	composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0416853A (pt)	2007-02-13	pirazolila e imidazolila pirimidinas
BRPI0414948A (pt)	2006-11-07	derivados de pirazolo-e-imidazo pirimidina
BRPI0413094A (pt)	2006-10-03	derivados de quinolina e seu uso em terapia
BR0212535A (pt)	2004-10-19	Compostos e composições como inibidores de catepsina
BRPI0508969A (pt)	2007-08-21	compostos orgánicos
BRPI0411308A (pt)	2006-07-11	composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BRPI0412862A (pt)	2006-10-03	derivados da nicotinamida úteis como inibidores de pde4
EA200702375A1 (ru)	2008-06-30	Производные мочевины, способы их получения и применения
BRPI0411087A (pt)	2006-07-25	aperfeiçoamentos em ou relacionados a compostos orgánicos
BR0113259A (pt)	2003-07-15	Processo para a preparação de um composto, composto e processo para a preparação de compostos
WO2004062562A3 (fr)	2004-09-16	Derives de diarylmethylidene piperidine, preparations et utilisations de ceux-ci

Legal Events

Date	Code	Title	Description
2012-05-29	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 7A E 8A ANUIDADES.
2013-02-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.